December 25, 2014 5:18 PM ET

Biotechnology

Company Overview of Receptos, Inc.

Company Overview

Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics for immune disorders. Its lead product includes RPC1063, an oral sphingosine 1-phosphate 1 receptor modulator that is in Phase II portion of Phase II/III studies for the treatment of relapsing multiple sclerosis; and is in Phase II studies to treat ulcerative colitis. The company is also developing RPC4046, a monoclonal antibody, which is in Phase II studies for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positiv...

10835 Road to the Cure

Suite 205

San Diego, CA 92121

United States

Founded in 2008

41 Employees

Phone:

858-652-5700

Fax:

858-587-2659

Key Executives for Receptos, Inc.

Chief Executive Officer
Age: 56
Total Annual Compensation: $451.6K
Co-Founder and Chief Scientific Officer
Age: 58
Total Annual Compensation: $231.1K
Chief Financial Officer and Principal Accounting Officer
Age: 44
Total Annual Compensation: $254.8K
Chief Medical officer
Age: 44
Total Annual Compensation: $364.3K
Compensation as of Fiscal Year 2013.

Receptos, Inc. Key Developments

Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis

Receptos, Inc. announced that the company has enrolled the first patient in the SUNBEAM Phase 3 trial of RPC1063 in patients with relapsing multiple sclerosis (RMS). The company had previously initiated the Phase 3 portion of the RADIANCE trial in patients with RMS. With both trials now actively enrolling patients, Receptos is on track to complete this Phase 3 clinical development program in 2017. The announcement follows the disclosure in September 2014 of the detailed Phase 2 results of RPC1063 in RMS. In that trial, RPC1063 met the primary endpoint of reduction in MRI brain lesion activity as well as secondary endpoints measuring effects on other MRI parameters. The overall safety profile of RPC1063 was consistent with the results of prior trials and continues to be differentiated on this basis from other oral agents for treatment of RMS. As with the RADIANCE trial, the SUNBEAM trial is a randomized, double-blind study designed to compare 0.5 mg and 1.0 mg of RPC1063 against interferon beta-1a (Avonex®) in 1,200 patients with RMS. The primary objective for the RADIANCE and SUNBEAM trials is to assess whether RPC1063 is superior to Avonex® in reducing the annualized relapse rate in patients after two years of therapy and one year of therapy, respectively. Both Phase 3 trials are being conducted under Special Protocol Assessment (SPA) agreement with the FDA.

Receptos, Inc.(NasdaqGS:RCPT) added to NASDAQ Biotechnology Index

Receptos, Inc. will be added to the NASDAQ Biotechnology Index.

Receptos, Inc. Announces Management Changes

On December 1, 2014, David Hinkle resigned as Senior Director, Finance & Controller and Chief Accounting Officer of Receptos, Inc. Graham Cooper, the company's Chief Financial Officer, has assumed the role of Principal Accounting Officer, effective immediately.

Similar Private Companies By Industry

Company Name Region
PETNET Solutions, Inc. United States
Angion Biomedica Corp. United States
Nano3D Biosciences, Inc. United States
Sorenson Genomics, LLC United States
Early Warning Technologies, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Receptos, Inc., please visit www.receptos.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.